The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Dexamethasone in Hospitalized Patients with Covid-19
Open accessPublished version of a preprint
Abstract
BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. METHODS: In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the final results of this assessment. RESULTS: A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55). CONCLUSIONS: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936; ISRCTN number, 50189673.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Until the release of the RECOVERY trial,66 patients with severe COVID-19 were not routinely treated with GC agonists such as dexamethasone.”
From Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy (2023) · cites this paper as [66]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, dexamethasone reduces the death rate of patients with severe COVID-19 (370).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [370]
In the citing paper
“These studies were, however, restricted to only publications up to August and October 2020—which is not representative of the current landscape of covid-19 research and which does not include the majority of evidence being currently used to guide covid-19 care, including critical trials of the effects of corticosteroids and interleukin 6 receptor blockers.”
From Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review (2022) · cites this paper as [2]
In the citing paper
“reports of hemophagocytosis and elevated cytokine levels — as well as beneficial effects of immunosuppressant agents — in affected patients, particularly those who are the most severely ill, suggest that cytokine storm may contribute to the pathogenesis of Covid-19.87,88”
From Cytokine storm (2020) · cites this paper as [88]
In the citing paper
“a recent randomized, controlled trial showing that dexamethasone reduces mortality among the most severe cases of Covid-19, characterized by elevated CRP levels and supplemental oxygen requirements, and potentially worsens outcomes in milder cases suggests that excessive, late-stage inflammation contributes to mortality.88”
From Cytokine storm (2020) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Research works printed but not linked: 2
- Corral-Gudino L Bahamonde A Arnaiz-Revillas F et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. June 18 2020 (https://www.medrxiv.org/content/10.1101/2020.06.17.20133579v1). preprint. · DOI
- Siemieniuk R, Rochwerg B, Agoritsas T, et al. A living WHO guideline on drugs for Covid-19. BMJ 2020;370:m3379-m3379.32887691
Cited by
Sorted by citations
Items 1,001–1,036 of 1,036
Clinical presentation and management of COVID ‐19
Thevarajan, I., Buising, K. L., & Cowie, B. C. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50698 · Cited by 73
Iglesias-Julián, E., López-Veloso, M., de-la-Torre-Ferrera, N., Barraza-Vengoechea, J. C., Delgado-López, P. D., Colazo-Burlato, M., Ubeira-Iglesias, M., Montero-Baladía, M., Lorenzo-Martín, A., Minguito-de-la-Iglesia, J., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102537 · Cited by 62
Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection
Creeden, J. F., Imami, A. S., Eby, H. M., Gillman, C., Becker, K. N., Reigle, J., Andari, E., Pan, Z. K., O’Donovan, S. M., McCullumsmith, R. E., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111437 · Cited by 61
Expert-Augmented computational drug repurposing identified baricitinib as a treatment for COVID-19
Smith, D. P., Oechsle, O., Rawling, M. J., Savory, E., Lacoste, A. M. B., & Richardson, P. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.709856 · Cited by 62
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem
Cho, J.-H., & Suh, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1951 · Cited by 63
Lu, R. X. Z., Lai, B. F. L., Rafatian, N., Gustafson, D., Campbell, S. B., Banerjee, A., Kozak, R., Mossman, K., Mubareka, S., Howe, K. L., et al. (2022) · Lab on a Chip · doi:10.1039/d1lc00817j · Cited by 58
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Liu, J., Budylowski, P., Samson, R., Griffin, B. D., Babuadze, G., Rathod, B., Colwill, K., Abioye, J. A., Schwartz, J. A., Law, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj9815 · Cited by 56
Tornling, G., Batta, R., Porter, J. C., Williams, B., Bengtsson, T., Parmar, K., Kashiva, R., Hallberg, A., Cohrt, A. K., Westergaard, K., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101152 · Cited by 54
Iqbal, Y., Al Abdulla, M. A., Albrahim, S., Latoo, J., Kumar, R., & Haddad, P. M. (2020) · BJPsych Open · doi:10.1192/bjo.2020.85 · Cited by 53
Rubin, G. A., Desai, A. D., Chai, Z., Wang, A., Chen, Q., Wang, A. S., Kemal, C., Baksh, H., Biviano, A., Dizon, J. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6842 · Cited by 54
The struggle of a good friend getting old: cellular senescence in viral responses and therapy
Kohli, J., Veenstra, I., & Demaria, M. (2021) · The EMBO Reports · doi:10.15252/embr.202052243 · Cited by 52
The LOVIT-COVID Investigators, O. B. O. T. C. C. C. T. G., Florescu, S., Stanciu, D., Zaharia, M., Kosa, A., Codreanu, D., Fareed, K., Kidwai, A., Kaye, C., Coutts, A., et al. (2023) · JAMA · doi:10.1001/jama.2023.21407 · Cited by 55
Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England
Perez-Guzman, P. N., Knock, E., Imai, N., Rawson, T., Santoni, C. N., Alcada, J., Whittles, L. K., Thekke Kanapram, D., Sonabend, R., Gaythorpe, K. A. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39661-5 · Cited by 42
Pathways to Severe COVID‐19 for People with Obesity
O’Rourke, R. W., & Lumeng, C. N. (2021) · Obesity · doi:10.1002/oby.23099 · Cited by 42
Fteropoulli, T., Kalavana, T. V., Yiallourou, A., Karaiskakis, M., Koliou Mazeri, M., Vryonides, S., Hadjioannou, A., & Nikolopoulos, G. K. (2025) · Journal of Clinical Nursing · doi:10.1111/jocn.15938 · Cited by 42
Zeraatkar, D., Pitre, T., Leung, G., Cusano, E., Agarwal, A., Khalid, F., Escamilla, Z., Cooper, M. A., Ghadimi, M., Wang, Y., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2022-000309 · Cited by 44
Papadimitriou-Olivgeris, M., Kolonitsiou, F., Kefala, S., Spiliopoulou, A., Aretha, D., Bartzavali, C., Siapika, A., Marangos, M., & Fligou, F. (2022) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2022.102353 · Cited by 39
Li, X., Liang, T., Dai, B., Chang, L., Zhang, Y., Hu, S., Guo, J., Xu, S., Zheng, L., Yao, H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci166795 · Cited by 41
Kleeman, S. O., Thakir, T. M., Demestichas, B., Mourikis, N., Loiero, D., Ferrer, M., Bankier, S., Riazat-Kesh, Y. J. R. A., Lee, H., Chantzichristos, D., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100347 · Cited by 37
COVID-19 research risks ignoring important host genes due to pre-established research patterns
Stoeger, T., & Nunes Amaral, L. A. (2020) · eLife · doi:10.7554/elife.61981 · Cited by 30
Yavropoulou, M. P., Filippa, M. G., Mantzou, A., Ntziora, F., Mylona, M., Tektonidou, M. G., Vlachogiannis, N. I., Paraskevis, D., Kaltsas, G. A., Chrousos, G. P., et al. (2022) · Endocrine · doi:10.1007/s12020-021-02968-8 · Cited by 33
Ivermectin for preventing and treating COVID-19
Popp, M., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017 · Cited by 31
Hayward, G., Yu, L.-M., Little, P., Gbinigie, O., Shanyinde, M., Harris, V., Dorward, J., Saville, B. R., Berry, N., Evans, P. H., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106130 · Cited by 31
Kim, J., Mukherjee, A., Nelson, D., Jozic, A., & Sahay, G. (2020) · doi:10.1101/2020.07.24.205583 · Cited by 28
Biering, S. B., Van Dis, E., Wehri, E., Yamashiro, L. H., Wrynla, X. H., Dugast-Darzacq, C., Graham, T. G. W., Stroumza, J. R., Golovkine, G. R., Roberts, A. W., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00017 · Cited by 28
Lobo, S. M., Plantefève, G., Nair, G., Joaquim Cavalcante, A., Franzin de Moraes, N., Nunes, E., Barnum, O., Berdun Stadnik, C. M., Lima, M. P., Lins, M., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102383 · Cited by 27
Lai, A., Chang, M. L., O'Donnell, R. P., Zhou, C., Sumner, J. A., & Hsiai, T. K. (2021) · Science of The Total Environment · doi:10.1016/j.scitotenv.2021.146464 · Cited by 25
Huang, J., Lai, H., Zhao, W., Xia, D., Bai, C., Sun, M., Liu, J., Liu, J., Pan, B., Tian, J., et al. (2025) · Journal of Medical Internet Research · doi:10.2196/70450 · Cited by 20
Why probability probably doesn’t exist (but it is useful to act like it does)
Spiegelhalter, D. (2024) · Nature · doi:10.1038/d41586-024-04096-5 · Cited by 19
Beyond dexamethasone, emerging immuno‐thrombotic therapies for COVID‐19
Jensen, M. P., George, M., Gilroy, D., & Sofat, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14540 · Cited by 17
Azar, K. M. J., Lockhart, S. H., Shen, Z., Romanelli, R., Brown, S., Smits, K., & Pressman, A. R. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab191 · Cited by 13
Cheng, Y.-C., Guerra, Y., Morkos, M., Tahsin, B., Onyenwenyi, C., Fogg, L., & Fogelfeld, L. (2021) · PLOS ONE · doi:10.1371/journal.pone.0256682 · Cited by 12
Sakamuru, S., Huang, R., & Xia, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935399 · Cited by 11
SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE: COVID-19 and Hematology
Kreidieh, F., & Temraz, S. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.078 · Cited by 7
Dorin, R. I., Urban, F. K., Perogamvros, I., & Qualls, C. R. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac173 · Cited by 4
Cell signaling pathways discovery from multi-modal data
He, C., Simpson, C., Cossentino, I., Zhang, B., Tkachev, S., Eddins, D. J., Kosters, A., Yang, J., Sheth, S., Levy, T., et al. (2025) · doi:10.1101/2025.02.06.636961 · Cited by 3
Metadata
- Authors
- The RECOVERY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-25
- Volume
- 384
- Issue
- 8
- Pages
- 693-704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7383595
- OpenAlex
- W3042270788
- Cited by
- 11,477
- References
- 43
- Citations by year
- 2026: 301 · 2025: 573 · 2024: 932 · 2023: 1534 · 2022: 2623 · 2021: 3849
- FWCI
- 316.80
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DiRROS repository (University of Maribor) (publishedVersion, cc-by)
- Repository@Nottingham (University of Nottingham) (publishedVersion, other-oa)
- Edinburgh Napier Research Repository (Edinburgh Napier University) (publishedVersion)
- Explore Bristol Research (publishedVersion, cc-by)
- ePrints Soton (University of Southampton) (acceptedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion)
- Edinburgh Napier Research Repository (Edinburgh Napier University) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- St Andrews Research Repository (St Andrews Research Repository) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- United Kingdom Research and Innovation (MC_PC_19056)
- National Institute for Health Research (MC_PC_19056)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- dexamethasone, COVID-19 pandemic, glucocorticoids, 28-day mortality, invasive mechanical ventilation, oxygen therapy, respiratory support, lung injury, anti-inflammatory therapy, hospitalized patients, RECOVERY trial, usual care comparison, treatment effect heterogeneity
- MeSH terms
- COVID-19, COVID-19 Drug Treatment, Administration, Oral, Aged, Aged, 80 and over, Anti-Infective Agents, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, United Kingdom, Hospitalization, Humans, Injections, Intravenous, Length of Stay, Male, Oxygen Inhalation Therapy, Respiration, Artificial, Odds Ratio, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
